The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
On Tuesday, Eli Lilly and Incyte Corp (INCY.O) announced that their COVID-19 drug baricitinib reduced the risk of death in patients on mechanical ventilation.
The FDA first approved Lilly’s baricitinib combined with Gilead Sciences’ (GILD.O) remdesivir to treat COVID-19 patients.
The FDA last month approved the drug alone or with remdesivir.
- Brief Anger Hampers Blood Vessel Function Leading to Increased Risk of Heart Disease and Stroke – New Study
- New Blood Test Pinpoints Future Stroke Risk – Study Identifies Inflammatory Molecules as Key Biomarker
- Enceladus: A Potential Haven for Extraterrestrial Life in its Hidden Ocean Depths
- New Experiment: Dark Matter Is Not As ‘DARK’ As All We Think
- Scientists in Fear of This New Predator From Red Sea Eating Native Species in Mediterranean
The study’s latest data shows that patients on ventilators who received baricitinib plus standard care were 46% less likely to die than those who received placebo plus standard care.
Lilly said the study’s findings will be shared with regulatory agencies in the US, EU, and elsewhere.
Source: Reuters
Image Credit: Getty
